Risk assessment in pulmonary arterial hypertension

European Respiratory Review

Volumn 25, Issue 142, 2016, Pages 390-398

  Raina, Amresh ^a   Humbert, Marc ^b,c,d  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c BICÊTRE HOSPITAL   (France)

^d CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL;

CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR MAGNETIC RESONANCE; CONNECTIVE TISSUE DISEASE; ECHOCARDIOGRAPHY; FAINTNESS; FUNCTIONAL STATUS; HEART CATHETERIZATION; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE FAILURE; HUMAN; LOSS OF FUNCTION MUTATION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERICARDIAL EFFUSION; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE ASSESSMENT; REVEAL RISK SCORE; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SIX MINUTE WALK TEST; SURVIVAL RATE; SYSTEMIC SCLEROSIS; DECISION SUPPORT SYSTEM; DISEASE COURSE; HEALTH STATUS; HYPERTENSION, PULMONARY; MORTALITY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; HEALTH STATUS; HUMANS; HYPERTENSION, PULMONARY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 85001052453     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0077-2016     Document Type: Review

References (52)

1. Wells BJ, Kattan MW, Cooper GS, et al. Colorectal cancer predicted risk online (CRC-PRO) calculator using data from the multi-ethnic cohort study. J Am Board Fam Med 2014; 27: 42-55.
2. Stelloo E, Bosse T, Nout RA, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer: a TransPORTEC initiative. Mod Pathol 2015; 28: 836-844.
3. Cazzoletti L, Corsico AG, Albicini F, et al. The course of asthma in young adults: a population-based nine-year follow-up on asthma remission and control. PLoS One 2014; 9: e86956.
4. Drazner MH, Velez-Martinez M, Ayers CR, et al. Relationship of right- to left-sided ventricular filling pressures in advanced heart failure: insights from the ESCAPE trial. Circ Heart Fail 2013; 6: 264-270.
5. McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol 2013;62: D73-D81.
6. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016; 37: 67-119.
7. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903-975.
8. Humbert M, Sitbon O, Yaici A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
9. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
10. Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 2012; 141: 354-362.
11. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
12. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
13. Launay D, Sitbon O, Le PJ, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 2010; 49: 490-500.
14. Mathai SC, Hassoun PM. Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin 2012; 8: 413-425.
15. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043-3050.
16. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-157.
17. Evans JD, Girerd B, Montani D, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med 2016; 4: 129-137.
18. Farber HW, Miller DP, Poms AD, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest 2015; 148: 1043-1054.
19. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
20. Ghofrani HA, Grimminger F, Grunig E, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016; 4: 361-371.
21. Barst RJ, Chung L, Zamanian RT, et al. Functional class improvement and three-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL registry. Chest 2013; 144: 160-168.
22. Taichman DB, McGoon MD, Harhay MO, et al. Wide variation in clinicians’ assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. Mayo Clin Proc 2009; 84: 586-592.
23. Farber HW, Miller DP, McGoon MD, et al. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant 2015; 34: 362-368.
24. Fritz J, Blair C, Oudiz R, et al. Baseline and follow-up six minute walk distance and BNP predict 2-year mortality in pulmonary arterial hypertension. Chest 2013; 143: 315-323.
25. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60: 1192-1201.
26. Gabler NB, French B, Strom BL, et al. Validation of six-minute-walk distance as a surrogate endpoint in pulmonary arterial hypertension trials. Circulation 2012; 126: 349-356.
27. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012; 39: 589-596.
28. Chia EM, Lau EM, Xuan W, et al. Exercise testing can unmask right ventricular dysfunction in systemic sclerosis patients with normal resting pulmonary artery pressure. Int J Cardiol 2016; 204: 179-186.
29. Blumberg FC, Arzt M, Lange T, et al. Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension. Eur J Heart Fail 2013; 15: 771-775.
30. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006; 174: 1034-1041.
31. Peacock AJ, Crawley S, McLure L, et al. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study. Circ Cardiovasc Imaging 2014; 7: 107-114.
32. Swift AJ, Rajaram S, Capener D, et al. Longitudinal and transverse right ventricular function in pulmonary hypertension: cardiovascular magnetic resonance imaging study from the ASPIRE registry. Pulm Circ 2015; 5: 557-564.
33. Han QJ, Witschey WR, Fang-Yen CM, et al. Altered right ventricular kinetic energy work density and viscous energy dissipation in patients with pulmonary arterial hypertension: a pilot study using 4D flow MRI. PLoS One 2015; 10: e0138365.
34. van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011; 58: 2511-2519.
35. Harbaum L, Hennigs JK, Baumann HJ, et al. N-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pre-capillary pulmonary hypertension and renal insufficiency. PLoS One 2014; 9: e94263.
36. Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007; 131: 402-409.
37. Halank M, Einsle F, Lehman S, et al. Exercise capacity affects quality of life in patients with pulmonary hypertension. Lung 2013; 191: 337-343.
38. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
39. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007; 30: 1103-1110.
40. Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007; 132: 373-379.
41. Thenappan T, Shah SJ, Rich S, et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35: 1079-1087.
42. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-109.
43. McGoon MD, Krichman A, Farber HW, et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc 2008; 83: 923-931.
44. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest 2010; 137: 376-387.
45. Sitbon O, Sattler C, Bertoletti L, et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J 2016; 47: 1727-1736.
46. Sitbon O, Jais X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014; 43: 1691-1697.
47. Benza RL, Miller DP, Foreman AJ, et al. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. J Heart Lung Transplant 2015; 34: 356-361.
48. Kane GC, Maradit-Kremers H, Slusser JP, et al. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest 2011; 139: 1285-1293.
49. Sitbon O, Benza RL, Badesch DB, et al. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J 2015; 46: 152-164.
50. Simonneau G, Channick RN, Delcroix M, et al. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J 2015; 46: 1711-1720.
51. Rubin LJ, Simonneau G, Badesch D, et al. The study of risk in pulmonary arterial hypertension. Eur Respir Rev 2012; 21: 234-238.
52. Lee KL, Pryor DB, Harrell FE Jr, et al. Predicting outcome in coronary disease. Statistical models versus expert clinicians. Am J Med 1986; 80: 553-560.